The U.S. FDA launched an investigation into Novartis's gene therapy Zolgensma after two pediatric patients developed tumors directly linked to vector DNA integration near the cancer-driving GLI1 oncogene. Novartis reported nine total tumor cases among over 6,000 treated children. The FDA extended scrutiny to Itvisma, an intrathecal version sharing the same AAV9 vector construct, but maintains that therapeutic benefits currently outweigh risks.
FDA regulatory response and position on Zolgensma
- ▪The FDA acknowledged field-wide AAV safety signals, including a January 2026 clinical hold on Regenxbio's RGX-111 program and an October 2026 report on Forge Biologics' FBX-101
- ▪On November 6, 2026, the FDA stated that the therapeutic benefits of Zolgensma and Itvisma continue to outweigh risks, maintaining approvals without issuing clinical holds or black-box warnings
- ▪The FDA launched a safety investigation into Novartis's Zolgensma and extended its evaluation to Itvisma, an intrathecal formulation using the same AAV9 vector approved in November 2025
Novartis reports Zolgensma tumor cases and integration findings
- ▪On November 5, 2026, Novartis disclosed nine reports of tumors in pediatric patients treated with Zolgensma gene therapy since its initial 2019 approval
- ▪In two of the nine Zolgensma tumor cases disclosed in November 2026, molecular testing confirmed that the AAV vector DNA integrated near cancer-driving genes, including the GLI1 oncogene
Mechanisms of AAV vector genomic integration
- ▪Vector DNA integration upstream of the GLI1 locus allows internal promoters to drive aberrant expression of GLI1, a transcription factor involved in cell cycle regulation and tumor growth
- ▪Adeno-associated virus (AAV) vector DNA typically persists episomally in cell nuclei, but random genomic integration occurs at estimated frequencies between one in 1,000 and one in 100,000 per cell genome
Zolgensma commercial reach and pricing
- ▪More than 6,000 children worldwide have received Novartis's Zolgensma single-dose gene therapy for spinal muscular atrophy since its approval in May 2019
- ▪Novartis reported combined Zolgensma Group sales of $1.071 billion during the first nine months of 2026, up from $925 million during the same period in 2025
- ▪Upon Zolgensma's approval by the FDA on May 24, 2019, Zolgensma carried a list price of approximately $2.1 million per patient
Novartis 2019 data investigation
- ▪An August 2019 FDA investigation revealed that Novartis had known of manipulated preclinical data before Zolgensma's approval and delayed informing regulators
- ▪The 2019 FDA investigation into Novartis's manipulated preclinical data for Zolgensma concluded without imposing any penalties
Early retroviral gene therapy safety
- ▪In the early 2000s, clinical trials for X-linked severe combined immunodeficiency were halted after four of ten patients developed leukemia due to gammaretroviral vector integration near the LMO2 and other T-cell proto-oncogenes
- ▪Following leukemia cases in early retroviral gene therapy trials, the FDA placed regulatory holds across the gammaretroviral gene therapy space
Story comments
Loading comments…